Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.
Applied DNA Sciences Inc (APDN) operates at the intersection of biotechnology, security technology, and personalized medicine, generating news across multiple business fronts. The company's dual focus on DNA-based authentication systems and pharmacogenomic testing means developments span regulatory compliance, technology partnerships, clinical service expansion, and capital market activities.
News coverage for Applied DNA Sciences typically includes updates on customer contracts for DNA authentication technology, partnerships with manufacturers or government agencies seeking supply chain security, and developments in the LineaRx pharmacogenomic testing business. As a company in capital-intensive sectors requiring ongoing technology validation and market penetration, announcements often involve financing activities, strategic partnerships, and milestone achievements in product development or market adoption.
Investors following APDN news should expect coverage of regulatory compliance matters, as the company operates both a CLIA-certified clinical laboratory and commercializes authentication technology across regulated industries. Material events disclosed through SEC filings provide insight into operational changes, strategic shifts, and business developments. The company's position in emerging technology markets means news may address market validation efforts, pilot programs with potential customers, and progress in establishing revenue-generating customer relationships.
This news feed aggregates announcements, regulatory filings, and market developments affecting Applied DNA Sciences, providing context for investors tracking the company's commercialization progress in both DNA security and pharmacogenomic testing markets.
Applied DNA Sciences (NASDAQ: APDN) announced a contract with Camp Chateaugay for its safeCircle™ pooled COVID-19 surveillance testing. This contract emphasizes the company's focus on COVID-19 testing in niche markets, supporting the reopening of summer camps while minimizing virus spread. Testing will be conducted prior to and during the camp sessions using PCR technology, offering results within 24 hours. The success of this initiative could enhance Applied DNA's market presence in the public health sector as schools and camps seek reliable testing solutions.
Applied DNA Sciences (NASDAQ: APDN) has announced the successful technical validation of all seven Research Use Only (RUO) mutation detection assays in its Linea™ COVID-19 Selective Genomic Surveillance™ (SGS) Mutation Panel. Tested on 125 COVID-19 positive samples with 100% concordance against Whole Genome Sequencing results, the SGS Panel targets mutations designated as ‘Substitutions of Therapeutic Concern’ by the CDC. The Company plans to seek EUA-authorization for the panel, which is designed to enhance variant surveillance in the context of rising COVID-19 variants.
Applied DNA Sciences, Inc. (NASDAQ: APDN) clarifies its newly authorized asymptomatic serial screening indication for the Linea COVID-19 Assay Kit. While individual patients do not need personal prescriptions, a blanket prescription from a healthcare provider is required. The company’s subsidiary, Applied DNA Clinical Laboratories, will assist clients in obtaining these prescriptions to comply with regulatory standards. The Linea Assay Kit is not FDA approved but authorized for emergency use in specific testing conditions.
Applied DNA Sciences (NASDAQ: APDN) reported a significant 384% revenue growth year-over-year for the second fiscal quarter, driven by strong demand for its COVID-19 diagnostics. The company launched a clinical trial for a LinearDNA COVID-19 vaccine aimed at the veterinary market and established a recurring revenue stream through its CertainT platform. They also expanded their COVID-19 testing capabilities, allowing for enhanced monitoring of SARS-COV-2 mutations. Future strategies include pushing for Emergency Use Authorization for their Selective Genomic Surveillance Panel and expanding their therapeutic pipeline.
Applied DNA Sciences (NASDAQ: APDN) announced the U.S. FDA has granted a re-issued Emergency Use Authorization (EUA) for its Linea™ COVID-19 Assay Kit, expanding its use for serial screening of asymptomatic individuals. This update allows testing without a prescription and enables individual result reporting. With CLIA certification for its Applied DNA Clinical Labs subsidiary, the company aims to support safer reopening strategies for schools and workplaces. The Assay Kit can now process thousands of samples daily, enhancing its market reach and testing capabilities.
Applied DNA Sciences (NASDAQ: APDN) announced that its subsidiary, Applied DNA Clinical Labs (ADCL), received CLIA certification for COVID-19 testing from the New York State Department of Health. This certification enables ADCL to conduct high-throughput diagnostic testing, enhancing its capacity to serve regional healthcare providers and boosting its safeCircle service's economics. The company aims to leverage this certification to broaden its COVID-19 testing and future diagnostic opportunities, with rapid turnaround times for results.
Applied DNA Sciences, Inc. (NASDAQ: APDN) plans to report its fiscal 2021 Q2 financial results on May 13, 2021, after market close. Management will discuss these results during a conference call at 4:30 p.m. ET. The LinearDNA platform, the company's proprietary PCR-based manufacturing system, is being commercialized for applications in diagnostics and drug development, including COVID-19 testing. The company will provide a telephonic replay of the call and will archive the webcast for up to one year.
Applied DNA Sciences (NASDAQ: APDN) announced significant results from a recent clinical trial of its LinearDNA vaccine candidate. The booster injection, administered 30 days post-prime vaccination, resulted in a more than 5-fold increase in SARS-CoV-2 neutralizing antibody levels among felines, surpassing previous predictions. The company plans to initiate a clinical trial for minks to tackle COVID-19 transmission risks. CEO Dr. James A. Hayward emphasized the promising implications of these results for both animal and human applications.
Applied DNA Sciences (NASDAQ: APDN) has secured a new firm fixed-price indefinite delivery contract valued at up to $1.04 million with the Defense Logistics Agency’s Product Test Center in Columbus, Ohio. This contract aims to support the DLA's counterfeit mitigation efforts by providing unique DNA marking services and quality control testing. This collaboration builds on their long-standing partnership since 2014, ensuring the integrity of products in critical sectors.
Applied DNA Sciences (NASDAQ: APDN) announced an amendment to its Master Services Agreement, doubling its maximum value for COVID-19 Assay Kits. The agreement ensures continued access for a customer’s surveillance testing program, with a purchase order for 16,000 tests supporting in-person graduation ceremonies in May 2021. CEO Dr. James A. Hayward emphasized the importance of proactive monitoring amid increasing vaccination rates and new virus variants. The Linea™ COVID-19 Assay Kit is FDA EUA authorized for specific respiratory specimens, aiding in the detection of SARS-CoV-2.
FAQ
What is the current stock price of Applied Dna Scie (APDN)?
What is the market cap of Applied Dna Scie (APDN)?
